Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HDM2020
- Development stage
- Phase 1
- Lead developer
- Hangzhou Zhongmei Huadong Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HDM2020 is a **novel antibody-drug conjugate (ADC)** developed to target **fibroblast growth factor receptor 2b (FGFR2b)** for the treatment of advanced solid tumors, especially those that overexpress FGFR2b such as **stomach cancer and squamous non-small cell lung cancer**. The drug utilizes a monoclonal antibody specifically directed at FGFR2b, conjugated to a **topoisomerase inhibitor** payload via a drug-antibody ratio (DAR) of 8, facilitating targeted cytotoxic activity against tumor cells. It is under development by Huadong Medicine and its subsidiary Hangzhou Zhongmei Huadong Pharmaceutical, with activity focused in China. HDM2020 represents a next-generation biopharmaceutical ADC, with global intellectual property and injectable formulation, aimed at improving therapeutic outcomes in refractory solid malignancies[1][3][5][7].
- Other names
- HDM-2020HDM2020HDM 2020
02
Targets
FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)
Beyond the preview
Go deeper on HDM2020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HDM2020.